Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers
Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate approved by the FDA in 2013 for advanced HER2-positive breast cancer treatment exhibiting promising clinical benefits. However, HER2 overexpression and gene amplification have also been reported in other cancers like gastric cancer, non...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Molecular Biosciences |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmolb.2023.1165781/full |
| _version_ | 1797829304130732032 |
|---|---|
| author | Yang Zheng Jiayu Zou Chen Sun Fu Peng Fu Peng Cheng Peng |
| author_facet | Yang Zheng Jiayu Zou Chen Sun Fu Peng Fu Peng Cheng Peng |
| author_sort | Yang Zheng |
| collection | DOAJ |
| description | Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate approved by the FDA in 2013 for advanced HER2-positive breast cancer treatment exhibiting promising clinical benefits. However, HER2 overexpression and gene amplification have also been reported in other cancers like gastric cancer, non-small cell lung cancer (NSCLC), and colorectal cancer. Numerous preclinical studies have also revealed the significant antitumor effect of T-DM1 on HER2-positive tumors. With the advancement in research, several clinical trials have been conducted to investigate the antitumor effect of T-DM1. In this review, we briefly introduced the pharmacological effects of T-DM1. We reviewed its preclinical and clinical studies, especially on other HER2-positive cancers, establishing what has been encountered between its preclinical and clinical studies. In clinical studies, we found that T-DM1 has a therapeutic value on other cancers. An insignificant effect was observed on gastric cancer and NSCLC, inconsistent with the preclinical studies. |
| first_indexed | 2024-04-09T13:19:21Z |
| format | Article |
| id | doaj.art-dd48f069c7bf4e6bb8ecdba8eeeed933 |
| institution | Directory Open Access Journal |
| issn | 2296-889X |
| language | English |
| last_indexed | 2024-04-09T13:19:21Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Molecular Biosciences |
| spelling | doaj.art-dd48f069c7bf4e6bb8ecdba8eeeed9332023-05-11T11:21:18ZengFrontiers Media S.A.Frontiers in Molecular Biosciences2296-889X2023-05-011010.3389/fmolb.2023.11657811165781Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancersYang Zheng0Jiayu Zou1Chen Sun2Fu Peng3Fu Peng4Cheng Peng5State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, ChinaState Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, ChinaState Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, ChinaChengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, ChinaSichuan University, Chengdu, Sichuan, ChinaState Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, ChinaAdo-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate approved by the FDA in 2013 for advanced HER2-positive breast cancer treatment exhibiting promising clinical benefits. However, HER2 overexpression and gene amplification have also been reported in other cancers like gastric cancer, non-small cell lung cancer (NSCLC), and colorectal cancer. Numerous preclinical studies have also revealed the significant antitumor effect of T-DM1 on HER2-positive tumors. With the advancement in research, several clinical trials have been conducted to investigate the antitumor effect of T-DM1. In this review, we briefly introduced the pharmacological effects of T-DM1. We reviewed its preclinical and clinical studies, especially on other HER2-positive cancers, establishing what has been encountered between its preclinical and clinical studies. In clinical studies, we found that T-DM1 has a therapeutic value on other cancers. An insignificant effect was observed on gastric cancer and NSCLC, inconsistent with the preclinical studies.https://www.frontiersin.org/articles/10.3389/fmolb.2023.1165781/fullT-DM1HER2+cancertherapeutic potentialtargeted therapy |
| spellingShingle | Yang Zheng Jiayu Zou Chen Sun Fu Peng Fu Peng Cheng Peng Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers Frontiers in Molecular Biosciences T-DM1 HER2+ cancer therapeutic potential targeted therapy |
| title | Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers |
| title_full | Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers |
| title_fullStr | Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers |
| title_full_unstemmed | Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers |
| title_short | Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers |
| title_sort | ado tratuzumab emtansine beyond breast cancer therapeutic role of targeting other her2 positive cancers |
| topic | T-DM1 HER2+ cancer therapeutic potential targeted therapy |
| url | https://www.frontiersin.org/articles/10.3389/fmolb.2023.1165781/full |
| work_keys_str_mv | AT yangzheng adotratuzumabemtansinebeyondbreastcancertherapeuticroleoftargetingotherher2positivecancers AT jiayuzou adotratuzumabemtansinebeyondbreastcancertherapeuticroleoftargetingotherher2positivecancers AT chensun adotratuzumabemtansinebeyondbreastcancertherapeuticroleoftargetingotherher2positivecancers AT fupeng adotratuzumabemtansinebeyondbreastcancertherapeuticroleoftargetingotherher2positivecancers AT fupeng adotratuzumabemtansinebeyondbreastcancertherapeuticroleoftargetingotherher2positivecancers AT chengpeng adotratuzumabemtansinebeyondbreastcancertherapeuticroleoftargetingotherher2positivecancers |